CD274 and non-small cell lung carcinoma: The base case analysis assumed a 50% uptake of adjuvant atezolizumab starting in 2024 and estimated that 240 recurrences would be avoided among PD-L1–high patients with stage II-IIIA NSCLC across Canada over 10 years.